Faculty of Health: Medicine, Dentistry and Human Sciences

Peninsula Medical School

2020-05-04

Clinical features and genetic risk of demyelination following anti-TNF treatment

Lin, S

http://hdl.handle.net/10026.1/15613

10.1093/ecco-jcc/jjaa104 Journal of Crohn's and Colitis Oxford University Press (OUP)

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.



Clinical features and genetic risk of demyelination following anti-TNF treatment

Journal:	Journal of Crohn's and Colitis
Manuscript ID	Draft
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Lin, Simeng; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology Green, Harry; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology Heerasing, Neel; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology Heerasing, Neel; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology Chanchlani, Neil; University of Exeter, Exeter IBD and Pharmacogenetics Research Group Hamilton, Benjamin; University of Exeter, Exeter IBD and Pharmacogenetics Research Group Hamilton, Benjamin; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology Walker, Gareth; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology Heap, Graham; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology Hebart, Jeremy; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology Hobart, Jeremy; University Hospitals Plymouth NHS Trust, Neurology Martin, Roswell; Gloucestershire Hospitals NHS Foundation Trust, Neurology Coles, Alasdair; University of Cambridge, Clinical Neurosciences Silverberg, Mark; Sinai Health System, Mount Sinai Hospital, Zane Cohen Centre for Digestive Diseases; Division of Gastroenterology, Department of Gastroenterology Chung-Faye, Guy; King's College Hospital NHS Foundation Trust, Department of Gastroenterology

	Cummings, Fraser; University Hospital Southampton NHS Foundation Trust, Gastroenterology Department Lytvyak, Ellina; University of Alberta, Medicine Andersen, Vibeke; University Hospital of Southern Denmark, Focused Research Unit for Molecular Diagnostic and Clinical Research; Universit of Southern Denmark, Institute of Molecular Medicine; University of Southern Denmark, IRS-Center Sønderjylland Wood, Andrew; University of Exeter, Medical School Tyrrell, Jessica; University of Exeter, Medical School Beaumont, Robin; University of Exeter, Medical School Weedon, Mike; University of Exeter, Precision Medicine Exeter Kennedy, Nicholas; University of Exeter, Exeter IBD and Pharmacogenetics Research Group Spiers, Alexander; Royal Devon and Exeter NHS Foundation Trust, Radiology Harrower, Timothy; Royal Devon and Exeter NHS Foundation Trust, Neurology Goodhand, James; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology Ahmad, Tariq; University of Exeter, Exeter IBD and Pharmacogenetics Research Group; Royal Devon and Exeter NHS Foundation Trust, Gastroenterology
Subject:	Genetics and molecular epidemiology, Epidemiology
Classifications:	Genetics and molecular epidemiology, Epidemiology

SCHOLARONE[™] Manuscripts

1 Clinical features and genetic risk of demyelination

2 following anti-TNF treatment

Title	Clinical features and genetic risk of demyelination following anti-TN
	treatment
Authors	*Simeng Lin MBChB ^{1,2} , *Harry D. Green PhD ¹ , *Peter Hendy MBBS ^{1,2}
Title Authors Affiliations	Neel M. Heerasing MBBS ^{1,2} , Neil Chanchlani MBChB ¹ , Benjamin Hamilto
	MBBS ¹ , Gareth J. Walker PhD ^{1,2} , Graham A. Heap PhD ^{1,2} , Jeremy Hobar
	PhD ³ , Roswell J. Martin MD ⁴ , Alasdair J. Coles PhD ⁵ , Mark S. Silverber
	PhD ⁶ , Peter M Irving MD ⁷ , Guy Chung-Faye PhD ⁸ , JR Fraser Cumming
	DPhil ⁹ , Ellina Lytvyak PhD ¹⁰ , Vibeke Andersen PhD ¹¹ , Andrew R Woo
	PhD ¹² , Jessica Tyrrell PhD ¹² , Robin N Beaumont PhD ¹² , Michael N
	Weedon PhD ¹² , Nicholas A. Kennedy MBBS ^{1,2} , Alexander Spiers BMBCh ¹
	Timothy Harrower PhD ¹⁴ , James R. Goodhand MBBS ^{1,2} , Tariq Ahma
	DPhil ^{1,2} on behalf of the PRED4 study group
	*These authors contributed equally and share co-first authorship
Affiliations	¹ IBD Pharmacogenetics Group, University of Exeter, Exeter, UK.
	² Department of Gastroenterology, Royal Devon and Exeter Hospital NH
	Foundation Trust, Exeter, UK
	³ Department of Neurology, University Hospitals Plymouth, Plymouth, U
	⁴ Department of Neurology, Gloucestershire Hospitals NHS Foundation
	Trust, Gloucester, UK
	⁵ Department of Clinical Neurosciences, University of Cambridge, UK
	⁶ Mount Sinai Hospital Inflammatory Bowel Disease Centre, University
	Toronto, Toronto, Canada
	⁷ Department of Gastroenterology, Guy's and St Thomas' NH
	Foundation Trust, London, UK
	⁸ Department of Gastroenterology, King's College Hospital, London, UK
	⁹ Department of Gastroenterology, Southampton General Hospita
	Southampton, UK
	¹⁰ Department of Medicine, University of Alberta, Edmonton, Albert

1
2
3
4
5
6
U
7
8
9
10
11
12
13
14
14
16
17
18
19
20
21
22
22 23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
50
39
40
41
42
43
44
45
46
40 47
48
49
50
51
52
53
54
54 55
56
57
58
59
60

	Canada				
	¹¹ Focussed Research Unit for Molecular Diagnostic and Clinical Resea				
IRS-Center Soenderjylland, University Hospital of Southern					
	Denmark				
	¹² University of Exeter Medical School, Exeter, UK				
	¹³ Department of Radiology, Royal Devon and Exeter Hospital NHS				
	Foundation Trust, UK				
	¹⁴ Department of Neurology, Royal Devon and Exeter Hospital NHS				
	Foundation Trust, Exeter, UK				
Address	for Dr Tariq Ahmad DPhil FRCP				
correspondence Gastroenterology Consultant, Royal Devon and Exeter Hospital Exeter IBD and Pharmacogenetics Research Group Research, Innovation, Learning and Development Centre Barrack Road, Exeter, United Kingdom, EX2 5DW Email : tariq.ahmad1@nhs.net ; Direct Dial: + 44 (0) 01392 406850					
Running title	Demyelination following anti-TNF treatment				
Key words	Demyelination, anti-TNF				
Word count	4299				
	2				

5 Authorship

6 All authors have made substantial contributions to all of the following: (1) the conception and design

7 of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or

8 revising it critically for important intellectual content, (3) final approval of the version to be

9 submitted

11 Contributions

A.S, T.H, N.A.K, J.R.G and T.A participated in the conception and design of the work. S.L, H.D.G, P.H,
N.M.H, N.C, B.H, G.J.W, G.A.H, J.H, R.M, A.C, M.S.S, P.M.I, G.C.F, J.F.C, E.L, A.R.W, J.T, R.N.B, M.W,
N.A.K, A.S, T.H, J.R.G and T.A were involved in the acquisition, analysis or interpretation of data. The
data analysis was performed by S.L and H.D.G. Drafting of the manuscript was conducted by S.L,
H.D.G, N.A.K, J.R.G and T.A. All the authors contributed to the critical review and final approval of

the manuscript. T.A obtained the funding for the study and is the guarantor of the article.

18 Abstract

19 Background and Aims

Anti-TNF exposure has been linked to demyelination events. We sought to describe the clinical features of demyelination events following anti-TNF treatment and test whether affected patients were genetically predisposed to multiple sclerosis (MS).

23 Methods

We conducted a case-control study to describe the clinical features of demyelination events following anti-TNF treatment. We compared genetic risk scores (GRS), calculated using carriage of 43 susceptibility loci for MS, in 48 cases to 1219 control patients exposed to an anti-TNF who did not develop demyelination events.

Results

Overall, 39 (73.6%) cases were female with a median age (range) at the time of demyelination of 41.5 years (20.7 – 63.2). The median duration of anti-TNF treatment was 21.3 (0.5-99.4) months and 19 (36%) patients were treated with concomitant immunomodulators. Most patients had central demyelination affecting the brain, spinal cord or both. Complete recovery was reported in 12 (22.6%) patients after a median time of 6.8 (0.1 - 28.7) months. After 31 months of follow-up partial recovery was observed in 29 (54.7%) patients, relapsing and remitting episodes in 9 (17.0%), progressive symptoms in 3 (5.7%): 2 (4%) patients were diagnosed with MS. There was no significant difference between MS GRS scores in cases (mean -3.5 x 10⁻⁴, SD 0.0039) and controls (mean -1.1×10⁻³, SD 0.0042) (p=0.23).

38 Conclusions

39 Patients who experienced demyelination events following anti-TNF had a similar genetic risk to anti-

40 TNF exposed controls who did not. Pharmacogenetic studies with prospective neuroimaging are

41 required to test whether demyelination events following anti-TNF are an idiopathic drug reaction.

43 Introduction

Anti-TNF therapies were licensed for use in 1998 and have revolutionised the management of inflammatory disorders. Case reports linking infliximab and etanercept to demyelination events followed and prompted the Food and Drug Administration and the European Medicines Agency to issue safety warnings^{1–3}. Contemporaneously, a randomised controlled trial of lenercept (a recombinant TNF receptor p55 immunoglobulin fusion protein) in patients with multiple sclerosis was discontinued early, because of the increased frequency of early and more severe demyelination exacerbations in the treatment compared with placebo arms ⁴.

Demyelination events have been reported with all licensed anti-TNF therapies in the treatment of patients with inflammatory bowel disease⁵, rheumatoid arthritis⁶ and psoriasis⁷. Because demyelination was rare in the respective registration trials it is not possible to conclude whether a causal association exists between anti-TNF therapies and demyelination events^{7,8}. Data from post-marketing adverse event registries seem to be reassuring, citing similar rates of demyelination to the background risk of multiple sclerosis⁹. However, these data are likely to underestimate rates of anti-TNF related demyelination because of confounding by voluntary reporting. In support of this assertion, data from a Danish population based-cohort study of patients with IBD treated with at least one anti-TNF reported a two-fold relative risk of demyelination events¹⁰. Moreover, because demyelination can be clinically silent the actual risk attributable to anti-TNF therapies maybe even higher. Evidence of demyelination was reported in 4% of patients with rheumatoid arthritis or spondyloarthopathies treated with anti-TNF after 18 months in whom pre-treatment MRI imaging was normal ¹¹.

64 Considerable uncertainty remains, therefore, as to whether anti-TNF exposure induces 65 demyelination in patients genetically pre-disposed to multiple sclerosis or is a chance observation 66 reflecting the evolution of de novo multiple sclerosis, or an idiosyncratic drug reaction. Moreover,

3 4	67	because symptomatic demyelination events following anti-TNF are uncommon their natural history
5 6 7	68	is poorly defined.
5 6 7 8 9 10 11 2 13 14 15 16 7 8 9 10 11 2 12 23 24 52 6 7 8 9 0 11 21 22 24 52 6 7 8 9 0 11 21 22 24 52 6 7 8 9 0 12 23 24 52 6 7 8 9 0 11 22 23 24 52 6 7 8 9 0 11 22 23 24 52 6 7 8 9 0 11 22 23 4 52 6 7 8 9 0 11 22 23 4 52 6 7 8 9 0 11 22 23 4 52 6 7 8 9 0 11 22 23 4 52 6 7 8 9 0 11 22 23 4 52 6 7 8 9 0 11 22 23 4 5 6 7 8 9 0 11 23 34 53 6 7 8 9 0 1 42 33 4 5 6 7 8 9 0 1 42 23 44 5 6 7 8 9 0 1 22 23 4 5 6 7 8 9 0 1 22 23 4 5 6 7 8 9 0 1 23 34 5 36 7 8 9 0 1 42 3 4 4 5 6 7 8 9 0 1 22 3 4 5 5 6 7 8 9 0 1 22 3 34 5 5 6 7 8 9 0 1 22 3 34 5 5 6 7 8 9 0 1 22 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	68	

70 Methods

71 Study design and setting

We conducted a retrospective case-control study to report the clinical features and natural history
 of demyelination events following anti-TNF therapy. We sought to assess whether demyelination
 events occurred in patients at increased genetic risk for multiple sclerosis.

75 Study populations

Potential cases were recruited from 41 UK and 6 international sites between 2012 and 2018.
Patients were identified through: opportunistic clinical encounters, cases reported to the British
Neurological Surveillance Unit (BNSU) or to the Medicine and Healthcare Products Regulatory
Authority pharmacovigilance scheme.

Inclusion criteria were all of the following: exposure to anti-TNF drug(s) without a preceding history of neurological symptoms suggestive of demyelination; neurological symptoms persisting for at least 24 hours following anti-TNF exposure; MRI brain and/or spinal cord imaging and/or or electrophysiological studies (nerve conduction or evoked potentials) consistent with central nervous system (CNS) or peripheral nervous system (PNS) disease, respectively; and neurological opinion implicating the anti-TNF drug as a cause of demyelination necessitating drug withdrawal if the patient was still receiving the drug.

Investigators at each site completed a custom-designed case report form (Supplemental Appendix 3), that captured the following data: patient demographics (age, weight, height, ethnicity, smoking and inflammatory disease history); drug exposure data (anti-TNF, anti-TNF dose, drug start date, drug stop date) and demyelination history (onset, duration, resolution, investigations and treatment).

Case report forms and supporting imaging and/or electrophysiological tests were reviewed independently by a panel including a neuro-radiologist and at least 2 neurologists. Consistent with our prior pharmacogenetic studies^{12–14} we modified the Liverpool Adverse Drug Reaction Causality Assessment Tool to verify cases (Supplemental Figure 1). "Possible" cases were defined as patients who had equivocal investigations or clinical features of demyelination. "Probable" cases demonstrated clinical, radiological and / or electrophysiological features of demyelination with a clear temporal relationship with anti-TNF therapy and no other cause for demyelination. In addition to these criteria, "definite" cases were individuals who had a recurrence of demyelination on anti-TNF therapy rechallenge. Cases assigned as "unlikely" were excluded. Definite, probable and possible cases were included in subsequent analyses. We classified patients according to whether they had central (brain and/or spinal cord) or peripheral nervous system involvement and whether their illness was a clinically isolated syndrome or had a relapsing phenotype. Clinically isolated syndrome was defined as a first episode of neurological symptom lasting for 24 hours and is caused by inflammation or demyelination in the central nervous system.

Patients recruited to the Personalising Anti-TNF Therapy in Crohn's disease (PANTS) study without a history of demyelination were used as controls. In brief, the PANTS study is a UK-wide, multicenter, prospective observational cohort study of 1610 patients with Crohn's disease treated with infliximab (originator, Remicade [Merck Sharp & Dohme, UK] and biosimilar, CT-P13 [Celltrion, South Korea]), and adalimumab (Humira [Abbvie, USA])¹⁵. To allow us to identify phenotypic factors associated with demyelination following anti-TNF therapy, each IBD case was matched to five anti-TNF exposed controls from the PANTS cohort by duration of anti-TNF therapy. Genetic risk scores for multiple sclerosis in all cases were compared to scores from control patients without neurological adverse events included in the genetics arm of the PANTS study.

115 Genetic methods

116 DNA was extracted from whole blood and genotyped using the Infinium Global Screening (cases) and 117 Illumina CoreExome microarrays (controls). Individuals of non-European ancestry were identified 118 using principal component analyses and excluded. Checks were made for relatedness using KING 119 1.9¹⁶.

Variants with a genotype call rate of <95%, a minor allele frequency of less than 1% or with significant evidence of deviation from Hardy-Weinberg equilibrium (P<1×10⁻⁶) were excluded. We corrected for batch-effect by removing variants with an uncorrected P value of < 0.05 for association with batch using Fisher's exact test. Palindromic variants were also removed prior to imputation leaving 130,132 genotyped variants. Single nucleotide polymorphisms were imputed using the Sanger Imputation Service to the Haplotype Reference Consortium (HRC) panel and a post-imputation information score of 0.9 was used as a cut-off. We constructed a multiple sclerosis genetic risk score (GRS) using data from previously identified risk variants¹⁷. Genetic risk scores were generated by summing the carriage status at each locus multiplied by the log odds ratio of that variant ^{18,19}. Susceptibility loci included in our GRS were defined as risk variants with a $p < 5 \times 10^{-6}$ and no closer in the genome than within 1 mega-base of another risk variant with a lower p-value. Overall, 51 loci were identified, details of their odds ratios and relative weightings are given in Supplemental Table 1.

We validated our GRS using subjects with multiple sclerosis identified in the UK Biobank, a study of over 500,000 individuals aged between 37 and 73 years recruited between 2006 and 2010²⁰. Multiple sclerosis cases were defined in the UK Biobank using either the ICD10 code G35, ICD9 code 340, or self-report code 1261. Those with other demyelinating conditions, defined by an ICD10 code of G36 / G37, ICD9 code of 341, or self-report code of 1397, were excluded. We validated the GRS in unrelated Europeans only. European ancestry was determined using principal components analysis and relatedness was determined using KING Kinship^{21,22}. Imputation was performed by the UK

Biobank²³. The dataset used for validation of the GRS contains 1680 multiple sclerosis cases and
387,932 controls.

142 Statistical methods

Pseudonymised data were managed using purpose designed electronic data capture tools at the Royal Devon and Exeter NHS Trust. Statistical analyses were undertaken in R 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria), PLINK version 1.90b3.42 and MATLAB version R2017a. All analyses were two tailed and P-values <0.05 were considered significant.</p>

147 Descriptive statistics were reported, based on normality, as mean (SEM) and median [IQR] for 148 continuous data and as proportions for categorical data. We included patients with missing clinical 149 data in analyses for which they had data and specified the denominator for each variable. Propensity 150 matching of IBD cases to PANTS controls on duration of anti-TNF drug exposure was undertaken 151 using the MatchIt package in R²⁴. We performed univariable analyses, using Fisher's exact test for 152 categorical data and Mann-Whitney U tests for continuous data, to identify clinical variables 153 associated with demyelination events in cases versus controls.

We tested for differences in MS genetic risk scores between cases and controls both in the UK Biobank and in our case-control study of patients exposed to anti-TNF, using Student's t-tests. Diagnostic performance of these scores was assessed using receiver operating characteristics (ROC) analyses. Fisher's exact test with Bonferroni correction was used to test association at each locus.

158 Ethical considerations

159 The protocol was approved by the National Research Ethics Committee (11/SW/0222, Exeter 160 pharmacogenetic PRED4 programme), and international sites sought local ethical approval 161 respectively. All participants involved provided informed written consent. Development and 162 validation of the GRS was conducted using data from the UK Biobank [application 41588].

Results

Study overview

Case disposition through the study is shown in Figure 1. Between 2012 and 2018, 66 patients were recruited from 41 UK and 6 international sites. Following adjudication, we excluded 13 (20%) patients: 7 (11%) in whom review of investigations refuted evidence of demyelination or a temporal relationship with anti-TNF exposure; and 6 (9%) in whom an alternative diagnosis was more likely (mycoplasma infection, hypertension, vitamin B12 deficiency, mononeuritis multiplex, multifocal acquired demyelinating sensory and motor neuropathy and myositis). Only one patient was rechallenged with an anti-TNF drug after a demyelination event.

Control subject disposition through the study is shown in Figure 1. Overall, 2.1% (34/1610) patients suffered a neurological adverse event during follow-up in the PANTS study and were excluded from this control cohort. The adverse event was attributed to the anti-TNF drug in 24/34 patients, leading to drug withdrawal in half; however, following neurological assessment none were diagnosed with demyelination.

177 After assessment using genetic quality control methods, we excluded 5 cases: 3 (6%) for non-white 178 European ethnicity and 2 (4%) for failure of genotyping. We did not identify relatives of third degree 179 or closer.

180 Clinical characteristics

The clinical features of verified cases are summarised in Table 1. Overall, 39 (73.6%) patients were female and 44 (83%) patients were white European. The median age (range) was 41.5 years (20.7 – 63.2). Thirteen (25%) were current and 13 (25%) were ex-smokers. The indication for anti-TNF therapy was IBD in 32 (60.4%), RA in 12 (22.6%), psoriasis or psoriatic arthropathy in 7 (13.2%), and ankylosing spondylitis in 5 (9.4%) patients, respectively. Three patients received anti-TNF therapy for more than one indication. Demyelination events followed treatment with infliximab in 25 (47%),

adalimumab in 19 (36%), etanercept in 7 (13%), golimumab in 1 (1.9%) and certolizumab in 1 (1.9%) patient(s), respectively. Concomitant immunomodulator use was observed in 19 (36%) cases, (thiopurine 8 (42%), methotrexate 8 (42%), ciclosporin 2 (10.5%), leflunomide 1 (5.3%). Overall, the median (range) duration of anti-TNF treatment prior to demyelination event was 21.3 [0.5-99.4] months.

Propensity matching in the subset of patients with IBD resulted in a median [IQR] duration of anti-TNF treatment prior to demyelination event of 9.9 [5.1 - 31.9] and 9.9 [5.1 - 25.2] months in cases and controls, respectively (p= 0.44). Cases were more likely to be female (84.4% [27/32] vs 57.5% [92/160], respectively, p = 0.008, Table 2) and were less likely to have been treated with a concomitant immunomodulator (immunomodulator 31% [10/32] vs 55.6% [89/160] respectively, p = 0.02). No differences were seen according to age, ethnicity, BMI or cigarette smoking.

Natural history of demyelination

Five patients had a family history of multiple sclerosis, although none were first degree relatives of a patient with multiple sclerosis. Four (8%) patients had a MRI brain or spinal cord before the onset of demyelination and none showed evidence of demyelination. The most common presentation was of central demyelination, observed in 44/53 (83.0%) patients. 31/44 (70.5%) patients with central demyelination had features in keeping with a clinically isolated syndrome (CIS). Of these 13/31 (41.9%) patients were noted to have a single lesion on MRI, and the remaining 18 (58.0%) multifocal lesions. Both cerebral and spinal lesions were noted (Figure 2).

The anti-TNF drug was withdrawn in all patients. In 24 (45.3%) patients no additional treatment was used, 21 (39.6%) patients received corticosteroids, 8 (15.1%) were treated with intravenous immunoglobulin and 4 (7.5%) patient received plasma exchange (Table 3). One patient who was re-treated with an anti-TNF developed symptoms of demyelination after each of two re-challenges. The median (range) duration of follow-up after the index demyelination event was 31 (2 - 171) months.

Complete recovery was reported in 12 (22.6%) patients after a median (range) time of 6.8 (0.1 -28.7) months. Partial recovery was observed in 29 (54.7%) patients, relapsing and remitting episodes in 9 (17.0%), and 3 (5.7%) patients experienced progressive symptoms. Overall, 2 (4%) patients were subsequently diagnosed with multiple sclerosis.

Genetic Analysis

After genetic imputation, we excluded 8 of the 51 target loci from the genetic risk score analyses: 6 loci because of poor imputation (INFO score <0.9) and 2 loci because they were not included in the HRC reference panel. The 43 loci that were used to construct our MS GRS are shown in Supplementary Table 1. We used this MS GRS in the UK Biobank and observed a significant difference between MS cases and controls ($p = 3.2 \times 10^{-116}$) (Figure 3) with an area under the curve (95% CI) of 0.65 (0.64 – 0.66) (Figure 4).

There was no significant difference in MS GRS scores between cases and controls (cases [mean -3.5 x 10⁻⁴, SD 0.0039] vs. controls [mean -1.1×10⁻³, SD 0.0042], p=0.23) (Figure 5). Moreover, no significant associations with demyelination were seen at any individual locus (Supplementary Table 2). We did not observe genomic inflation for the SNPs used in our GRS (Supplementary Figure 2). The AUC (95% CI) for predicting anti-TNF related demyelination in our cases compared with PANTS control subjects was 0.55 (0.46 - 0.64) (Figure 4).

229 Discussion

230 Key results

Anti-TNF exposed patients who suffered demyelination events were more likely to be female and less frequently treated with an immunomodulator. Patients who developed demyelination events had similar genetic risk scores for multiple sclerosis to control patients who did not develop demyelination events after anti-TNF therapy. Following almost three years of follow-up, about half of our demyelination cases had received one or more treatments for demyelination and a quarter had ongoing neurological symptoms.

237 Interpretation

Shared genetic susceptibility between autoimmune and inflammatory conditions may account for the increased risk of multiple sclerosis reported in patients with RA and IBD^{25,26}. Previous genetic studies of anti-TNF induced demyelination are limited to a negative candidate gene study of TNFRSF1A in patients with RA²⁷. Here, we have shown that anti-TNF treated patients who developed demyelination events had overlapping genetic risk scores for multiple sclerosis with anti-TNF exposed controls who did not develop demyelination. It is unlikely, then, that anti-TNF therapies lead to demyelination only in individuals genetically pre-disposed to multiple sclerosis. In support of this assertion only two cases in our study were subsequently diagnosed with multiple sclerosis.

There was a female predominance amongst patients with demyelination following treatment with anti-TNF therapies. We did not observe any other classical risk factors for multiple sclerosis arguing against the hypothesis that these events represent the chance development of de novo multiple sclerosis. For example compared to previously reported case series of patients with multiple sclerosis our cases were older ²⁸, less likely to be cigarette smokers ²⁹ and no one reported a first degree relative with multiple sclerosis ³⁰ . In support of anti-TNF related demyelination being an

adverse drug reaction, we observed rapid recurrence of neurological symptoms in the one individual who was re-challenged with an anti-TNF drug after a demyelination event.

Limitations and generalisability

Our study has several strengths including rigorous cross-disciplinary independent case verification, and for the first time we explored the value of an MS GRS in a study of anti-TNF related demyelination. We acknowledge, however, the following important limitations: first, in keeping with all case-control studies our data are susceptible to recall bias, with greater recruitment of more severe cases. Second, because this was a convenience sample, we were unable to report the incidence of demyelination events. However, in our prospectively collected control cohort of 1610 patients, 2% reported neurological symptoms during follow-up although none were confirmed as being due to demyelination. Third, our retrospective data collection from medical records is subject to missingness and interpretation bias. Fourth, our genetic analyses were limited to patients of white European ancestry and only patients with Crohn's disease made up the control cohort, which limits the generalisability of our findings. Finally, despite the study being open for six years we accept that our sample size was too small to permit a pharmacogenetic genome wide association study to identify novel variants associated with anti-TNF related demyelination and we were also underpowered to detect a difference in our cases and MS cases from the UK Biobank.

272 Conclusion

 This large case-control study adds comprehensive clinical information to the existing reports of demyelinating events associated with anti-TNF therapy for inflammatory disorders. Demyelination events were no more common in patients at genetic risk for multiple sclerosis. Further pharmacogenetic studies, with prospective neuroimaging are required to test whether anti-TNF related demyelination is an idiopathic drug reaction.

278 Acknowledgements

The authors would like to acknowledge Professor Nicholas Gutwoski and the British Neurological Surveillance Unit (BNSU) for their help with the recruitment of patients, and the use of the University of Exeter High-Performance Computing [HPC] facility in carrying out this work.

282 Financial disclosure

SL has received meeting support fees from Pfizer and Ferring; G.J.W has consulted for AbbVie and received honoraria from Falk and AbbVie for unrelated topics and a fellowship from NIHR; G.A.H reports non-financial support from AbbVie, outside the submitted work; and that he is now an employee of AbbVie and owns stock in the company. N.C is funded by Crohn's and Colitis UK fellowship; J.H. has received consulting fees, honoraria, support to attend meetings or research support from Acorda, Asubio, Bayer Schering, Biogen Idec, F. Hoffmann-La Roche, Genzyme, Merck Serono, Novartis, Oxford Health Policy Forum, Oxford PharmaGenesis and Teva. PMI has received lecture fees from Abbvie, Warner Chilcott, Ferring, Falk Pharma, Takeda, MSD, Johnson and Johnson, Shire and Pfizer, financial support for research from MSD, Takeda and Pfizer. Advisory fees: Abbvie, Warner Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira, Samsung Bioepis. N.A.K has consulted for Falk and received honoraria from Falk, Allergan, Pharmacosmos and Takeda for unrelated topics and is a deputy editor of Alimentary

 Pharmacology & Therapeutics Journal; J.R.G received honoraria from Falk, Abbvie and Shield
therapeutics for unrelated topics; T.A has received unrestricted research grants, advisory board fees,
speaker honorariums and support to attend international meetings from AbbVie, Merck, Janssen,
Takeda, Ferring, Tillotts, Ferring, Pfizer, NAPP, Celltrion, Hospira for unrelated topics; no financial
relationships with any organizations that might have an interest in the submitted work in the
previous three years. H.D.G, B.H, P.H, N.M.H, R.J.M, A.J.C, M.S.S, G.C.F, F.C, E.L, A.R.W, J.T, R.N.B,
M.N.W, A.S, T.H have no conflicts of interest to declare.

FOR REVIEW ONL

References

1. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec;44(12):2862-9.

- 2. The European Agency for the Evaluation of Medicinal Products. Revised EMEA Public Statement on Etanercept (Enbrel) - serious Hematological Reactions and Demyelination disorders. 2000.
- 3. Centocor Inc. REMICADE (infliximab) [package insert]. US Food Drug Adm website. 2002;(SUPPL-5004).
- Arnason BGW. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter 4. study. Neurology. 1999 Aug 11;53(3):457–65.
- 5. Andersen NN, Caspersen S, Jess T, Munkholm P. Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study. J Crohn's Colitis. 2008 Dec 1;2(4):304-9.
- Dreyer L, Magyari M, Laursen B, Cordtz R, Sellebjerg F, Locht H. Risk of multiple sclerosis during tumour 6. necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry. Ann Rheum Dis. 2016 Apr 1;75(4):785-6.
- Zhu TH, Nakamura M, Abrouk M, Farahnik B, Koo J, Bhutani T. Demyelinating disorders secondary to 7. TNF-inhibitor therapy for the treatment of psoriasis: A review. Vol. 27, Journal of Dermatological Treatment. Taylor and Francis Ltd; 2016. p. 406–13.
- Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor 8. (TNF). Clin Exp Rheumatol. 2004;22(5 SUPPL. 35).
- 9. Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, et al.

1 2			
2 3 4	324		Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from
5 6 7	325		BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. YSARH. 2011;40:330–7.
8 9 10	326	10.	Nyboe Andersen N, Pasternak B, Andersson M, Nielsen NM, Jess T. Risk of Demyelinating Diseases in
10 11 12	327		the Central Nervous System in Patients With Inflammatory Bowel Disease Treated With Tumor
12 13 14 15	328		Necrosis Factor Inhibitors. JAMA Intern Med. 2015 Dec 1;175(12):1990.
16 17	329	11.	Kaltsonoudis E, Zikou AK, Voulgari P V, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurological adverse
18 19	330		events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.
20 21	331		Arthritis Res Ther. 2014 Jun 17;16(3):R125.
22 23			
23 24 25	332	12.	Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, et al. Clinical features and HLA association of
26 27	333		5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease. J Crohns Colitis. 2015
28 29 30	334		Nov;10(2):149–58.
31 32	335	13.	Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, et al. HLA-DQA1-HLA-DRB1
33 34	336		variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet.
35 36 37	337		2014 Oct;46(10):1131–4.
38			
39 40	338	14.	Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, et al. Association of Genetic
41 42	339		Variants in NUDT15 with Thiopurine-Induced Myelosuppression in Patients with Inflammatory Bowel
43 44 45	340		Disease. JAMA - J Am Med Assoc. 2019 Feb 26;321(8):753–61.
46 47	341	15.	Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF
48 49	342		treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective,
50 51 52 53	343		multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;1253(19):1–13.
54 55	344	16.	Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust relationship inference in
56 57	345		genome-wide association studies. Bioinformatics. 2010 Nov 15;26(22):2867–73.
58			
59 60			
			20

Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, et al. Analysis of

immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet.

1	
2 3	346
4 5	347
6 7	348
8 9	
10 11	349
12 13	350
14 15	
16 17	351
18 19	352
20 21	353
22 23	
24 25	354
26 27	355
28 29	356
30 31	
32 33	357
34 35	358
36 37	
38	359
39 40	360
41 42	261
43 44	361
45 46	362
47 48	363
49 50	364
51 52	504
53 54	365
55 56	366
57	
59	
58	

17.

2013;45(11):1353-62.

9	18.	Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide
0		association studies. Genome Res. 2007 Oct;17(10):1520–8.
1	19.	Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic
2		variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009 Aug 6;460(7256):748-
3		52.
4	20.	Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource
5		for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015
6		Mar;12(3):e1001779.
7	21.	Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust relationship inference in
8		genome-wide association studies. Bioinformatics. 2010/10/05. 2010 Nov 15;26(22):2867–73.
9	22.	Tyrrell J, Jones SE, Beaumont R, Astley CM, Lovell R, Yaghootkar H, et al. Height, body mass index, and
0		socioeconomic status: mendelian randomisation study in UK Biobank. BMJ. 2016 Mar 8;352:i582.
1	23.	Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep
2		phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9.
3	24.	Ho DE, Imai K, King G, Stuart EA. Matchlt: Nonparametric preprocessing for parametric causal
4		inference. J Stat Softw. 2011 Jun 14;42(8):1–28.
5	25.	Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory
6		bowel disease. Gastroenterology. 2005 Sep 1;129(3):819–26.

1					
2 3 4	367	26.	Toussirot E, Pertuiset E, Martin A, Melac-ducamp S, Alcalay M, Grardel B, et al. The Journal of		
5 6	368		Rheumatology Association of rheumatoid arthritis with multiple sclerosis : report of 14 cases and		
7 8	369		discussion of its significance . The Journal of Rheumatology is a monthly international serial edited by		
9 10 11	370		Earl D . Silverman featuring research. 2006;33(5).		
12 13	371	27.	Bitoun S, Miceli-Richard C, Verstuyft C, Juge PA, Dieudé P, Berthelot J-M, et al. Frequency of tumour		
14 15 16	372		necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with		
16 17 18	373		rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications.		
19 20 21	374		Ann Rheum Dis. 2018 Dec 1;77(12):1835–6.		
22 23	375	28.	Palace J. MAKING THE DIAGNOSIS OF MULTIPLE SCLEROSIS. J Neurol Neurosurg Psychiatry. 2001 Dec		
24 25 26	376		1;71(suppl 2):ii3–8.		
27 28 29	377	29.	Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use,		
30 31 32	378		increases the risk of multiple sclerosis. Neurology. 2009;73(9):696–701.		
33 34	379	30.	Kahana E. Epidemiologic studies of multiple sclerosis: A review. Vol. 54, Biomedicine and		
35 36 37 38	380		Pharmacotherapy. Elsevier Masson SAS; 2000. p. 100–2.		
39 40 41 42 43 44 45 46 47 48 50 51 52 53 54 55 56	381				
57 58 59 60			22		


382 Figures and Tables

1 2 3

4

5

383 Figure 1. Flow diagram and Study Overview of Case and Control Cohorts









Figure 3. Probability distribution of genetic risk scores (GRS) in patients with multiple sclerosis in the UK Biobank

1 2 3









Characteristic	Cases
Patients, n	53
Gender	
Female	39 (73.6%)
Male	14 (26.4%)
Age	
Mean (SD)	40.6 (10.5)
Median [Min, Max]	41.5 [20.7, 63.2
Ethnicity	
White	44 (83.0%)
Other white background	4 (7.5%)
Mixed white and asian	2 (3.8%)
Any other Asian	2 (3.8%)
Carribean	1 (1.9%)
BMI	
Mean (SD)	25.7 (5.47)
Median [Min, Max]	24.9 [18.0, 43.2
Missing	5 (9.4%)
Condition	
IBD	32 (60.4%)
RA	12 (22.6%)
Psoriasis	7 (13.2%)
AS	5 (9.4%)
Drug	5 (5.470)
Infliximab	25 (47.2%)
Adalimumab	19 (35.8%)
Etanercept	7 (13.2%)
Certrolizumab	1 (1.9%)
Golimumab	1 (1.9%)
Family History	F (0, 40()
Yes	5 (9.4%)
No	42 (79.2%)
Smoking	
Current	13 (24.5%)
Ex	13 (24.5%)
Never	21 (39.6%)
Immunomodulator	
Yes	19 (35.8%)
No	34 (64.2%)

Mean (SD)	28.2 (27.7)	
Median [Min, Max]	21.3 [0.460, 99.4]	

402 Table 2. Characteristics of anti-TNF exposed inflammatory bowel disease cases and control

n = 32 n = 160 Sex Female 27 (84.4%) 92 (57.5%) 0.008 Male 5 (15.6%) 68 (42.5%) 0.208 Age (median [IQR]) 34.1 [29.5, 46.5] 33.9 [25.0, 48.0] 0.542 BMI (median [IQR]) 23.6 [20.6, 27.1] 24.1 [20.3, 28.9] 0.539 Smoking Current 6 (22.2%) 27 (17.1%)	Characteristic (IBD patients)	Case	Control	<i>p</i> value
Female27 (84.4%)92 (57.5%) $_{0.008}$ Male5 (15.6%)68 (42.5%)0.008Age (median [IQR])34.1 [29.5, 46.5]33.9 [25.0, 48.0]0.542BMI (median [IQR])23.6 [20.6, 27.1]24.1 [20.3, 28.9]0.539Smoking </th <th></th> <th>n = 32</th> <th>n = 160</th> <th></th>		n = 32	n = 160	
Male 5 (15.6%) 68 (42.5%) 0.008 Age (median [IQR]) 34.1 [29.5, 46.5] 33.9 [25.0, 48.0] 0.542 BMI (median [IQR]) 23.6 [20.6, 27.1] 24.1 [20.3, 28.9] 0.539 Smoking 0.008 0.542 0.539 Smoking 0.008 0.539 0.539 Current 6 (22.2%) 27 (17.1%) 0.75 Ex 9 (33.3%) 50 (31.6%) 0.75 Never 12 (44.4%) 81 (51.3%) 0.02				
Male 5 (15.6%) 68 (42.5%) Age (median [IQR]) 34.1 [29.5, 46.5] 33.9 [25.0, 48.0] 0.542 BMI (median [IQR]) 23.6 [20.6, 27.1] 24.1 [20.3, 28.9] 0.539 Smoking 27 (17.1%) 0.75 0.75 Ex 9 (33.3%) 50 (31.6%) 0.75 Never 12 (44.4%) 81 (51.3%) 0.02	Female	27 (84.4%)	92 (57.5%)	0.008
BMI (median [IQR]) 23.6 [20.6, 27.1] 24.1 [20.3, 28.9] 0.539 Smoking Current 6 (22.2%) 27 (17.1%) 0.75 Ex 9 (33.3%) 50 (31.6%) 0.75 Never 12 (44.4%) 81 (51.3%) 0.02	Male	5 (15.6%)	68 (42.5%)	0.008
Smoking 27 (17.1%) Ex 9 (33.3%) 50 (31.6%) 0.75 Never 12 (44.4%) 81 (51.3%) 0.02	Age (median [IQR])	34.1 [29.5, 46.5]	33.9 [25.0, 48.0]	0.542
Current6 (22.2%)27 (17.1%)Ex9 (33.3%)50 (31.6%)0.75Never12 (44.4%)81 (51.3%)0.02Concurrent immunomodulator10 (31.2%)89 (55.6%)0.02	BMI (median [IQR])	23.6 [20.6, 27.1]	24.1 [20.3, 28.9]	0.539
Ex 9 (33.3%) 50 (31.6%) 0.75 Never 12 (44.4%) 81 (51.3%) 0.02 Concurrent immunomodulator 10 (31.2%) 89 (55.6%) 0.02	Smoking			
Never 12 (44.4%) 81 (51.3%) Concurrent immunomodulator 10 (31.2%) 89 (55.6%) 0.02	Current	6 (22.2%)	27 (17.1%)	
Concurrent immunomodulator 10 (31.2%) 89 (55.6%) 0.02	Ex	9 (33.3%)	50 (31.6%)	0.75
	Never	12 (44.4%)	81 (51.3%)	
	Concurrent immunomodulator	10 (31 2%)	89 (55 6%)	
				0.02
		Revie		0.02

https://mc.manuscriptcentral.com/ecco-jcc


Table 3. Clinical characteristics of demyelination events in anti-TNF exposed cases

Characteristic of demyelinatio	n events	Cases (n = 53)
Investigations		
Lumbar puncture		32 (60.4%)
Nerve conduction studies		8 (15.1%)
Electrophysiology		19 (35.8%)
Treatment		
Steroids		21 (39.6%)
IVIG		8 (15.1%)
Plasma exchange		4 (7.5%)
None		24 (45.3%)
Other		1 (1.9%)
Time to recovery (Months)		
Mean (SD)	< ·	8.30 (8.54)
Median [Min, Max]	0	6.75 [0.10, 28.7
Duration of follow-up (Months	5)	
Mean (SD)		38.8 (33.7)
Median [Min, Max]	7	31.0 [2.00, 171]

Supplemental – Table of Contents


SUPPLEMENTAL FIGURE 1. ADJUDICATION ASSESSMENT TOOL	2
SUPPLEMENTAL FIGURE 2. QUANTILE-QUANTILE (QQ) PLOT DEMONSTRATING GENOMIC INFLATION FACTOR OF THE SINGLE	
NUCLEOTIDE POLYMORPHISMS (SNPS) INCLUDED IN THE MULTIPLE SCLEROSIS GENETIC RISK SCORE (GRS)	3
SUPPLEMENTAL TABLE 1. MS SUSCEPTIBILITY LOCI AND THEIR LOG ODDS RATIO THAT WERE USED TO CONSTRUCT A MS GENETIC	
RISK SCORE (GRS)	4
SUPPLEMENTAL TABLE 2. LOCATION, EFFECT ALLELE, FREQUENCY AND STATISTICS OF EACH INDIVIDUAL LOCUS IN THE MS GENET	IC
RISK SCORE (GRS) IN ORDER OF P VALUE	6
SUPPLEMENTAL APPENDIX 1. PARTICIPANTS OF ADJUDICATION MEETINGS	8
SUPPLEMENTALAPPENDIX 2: PRED4 STUDY GROUP MEMBERS	9
SUPPLEMENTAL APPENDIX 3. CASE REPORT FORM	12

Supplemental Figure 1. Adjudication assessment tool



Adapted version of the Liverpool Adverse Drug Reaction Causality Assessment Tool used in the adjudication process. Adapted from Gallagher *et al.* (Gallagher, R.M. *et al.* Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. *PLoS One*, e28096, 2011).

 Supplemental Figure 2. Quantile-Quantile (QQ) plot demonstrating genomic inflation factor of the single nucleotide polymorphisms (SNPs) included in the multiple sclerosis genetic risk score (GRS)



Supplemental Table 1. MS susceptibility loci and their log odds ratio that were used to construct a MS Genetic Risk Score (GRS)

Chromosome: Base Pair	Effect Allele	Log Odds Ra
6:32119898	Α	0.376212
6:27861670	Α	0.130655
6:27037080	A	0.114944
6:28413491	G	0.090611
1:85746993	A	0.085647
1:92975464	А	0.078819
2:231115454	С	0.067815
7:37382465	С	0.064832
3:28078571*	A	0.062206
17:57816757	А	0.058426
12:6440009	G	0.058426
6:137452908	G	0.056905
7:27014988	С	0.056142
5:176788570	G	0.053463
6:36375304	G	0.052694
8:79575804	A	0.049993
19:16505106	G	0.048053
7:28172739	С	0.048053
11:71168073	A	0.046495
11:60793330	A	0.045714
6:135739355	A	0.04454
3:159691112	G	0.043755
12:9905690	G	0.043362
17:40530763	A	0.041787
8:128192981	G	0.041787
16:30130493*	A	-0.04062
5:40399096	A	-0.04177
11:118724894*	A	-0.0422
10:94481917	A	-0.04374
2:191974435	A	-0.04455
7:50325567*		-0.04494
2:61095245	G	-0.04687
5:35879156	Q	-0.04803
6:138244816	G	-0.04803
8:128815029	Q	-0.04842
1:200874728	G	
5:55440730	G	-0.05037 -0.05076
	A	
12:58182062* 19:10742170		-0.05537
	A	-0.05576
1:2525665	G	-0.05616
3:121543577	A	-0.05844
6:159470559	A	-0.06068
19:18285944	A	-0.06143
19:6668972*	A	-0.06596
1:192541472	G	-0.07043
3:119222456	G	-0.07557

5	
6	
7	
8	
9	
10	
11	
12	
13	
14 15	
15 16	
16 17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27 28	
28 29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41 42	
42 43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	

1	.0:6099045	G	-0.08244
1	6:11194771	Α	-0.08386
1	4:88432328*	Α	-0.11759
1	:117080166*	С	-0.12709
6	:29904929	C	-0.15808

*denotes Single Nucleotide Polymorphisms (SNP) that failed genetic quality control checks

to Review only

Supplemental Table 2. Location, effect allele, frequency and statistics of each individual locus in the MS Genetic Risk Score (GRS) in order of p value

Chromosome	Basepair	Allele 1	Allele	Allele	Allele 2	p- value	Odds Ratio
			frequency of cases	frequency of controls			
11	60793330	A	0.5106	0.3827	G	0.01718	1.683
19	18285944	A	0.3723	0.2742	G	0.04549	1.57
17	40530763	A	0.4255	0.3415	G	0.09778	1.428
6	13573935	A	0.4255	0.35	C	0.1525	1.376
0	5		0.4255	0.55		0.1525	1.570
6	29904929	С	0.2872	0.3633	А	0.1546	0.7062
3	15969111 2	G	0.5106	0.4363	A	0.169	1.348
17	57816757	A	0.5426	0.4657	G	0.1708	1.361
5	35879156	A	0.2021	0.2597	С	0.2311	0.7222
1	2525665	G	0.3085	0.371	А	0.2325	0.7565
5	55440730	Α	0.1809	0.2323	G	0.2642	0.7298
3	11922245 6	С	0.2447	0.198	G	0.2922	1.312
5	40399096	Α	0.3723	0.321	G	0.3123	1.255
6	13824481 6	G	0.266	0.2214	A	0.3131	1.274
6	15947055 9	A	0.4362	0.3871	Т	0.3346	1.225
5	17678857 0	G	0.3085	0.3552	A	0.3808	0.8098
7	28172739	С	0.1809	0.2202	A	0.4455	0.782
6	13745290 8	G	0.2234	0.2621	A	0.4729	0.8099
7	37382465	С	0.1277	0.1048	A	0.4924	1.25
1	19254147 2	С	0.1489	0.1827	G	0.4953	0.7831
16	11194771	A	0.2979	0.3343	G	0.5048	0.8449
2	19197443 5	A	0.3191	0.3548	G	0.5112	0.8523
2	23111545 4	С	0.234	0.2069	G	0.5181	1.172
19	10742170	A	0.234	0.2081	G	0.5201	1.163
11	71168073	A	0.2447	0.2194	G	0.5288	1.153
6	27037080	A	0.06383	0.08871	G	0.5754	0.7004
2	61095245	G	0.2979	0.3286	A	0.5769	0.8667
1	92975464	A	0.1596	0.1411	G	0.6505	1.156
8	12819298 1	G	0.3723	0.3488	A	0.66	1.108
12	9905690	G	0.3936	0.3694	A	0.6638	1.108
6	27861670	A	0.07447	0.08992	G	0.7151	0.8143
8	12881502 9	A	0.2979	0.2827	G	0.7278	1.077
3	12154357 7	A	0.3723	0.3548	С	0.7425	1.079
10	94481917	A	0.3617	0.3806	G	0.7464	0.922
7	27014988	C	0.1489	0.1665	A	0.7776	0.8758
19	16505106	G	0.3191	0.306	A	0.8198	1.063

6	28413491	G	0.3723	0.3609	А	0.8274	1.051
6	32119898	Α	0.1489	0.1448	G	0.8815	1.034
6	36375304	G	0.1809	0.1766	А	0.8907	1.029
10	6099045	G	0.2553	0.2669	А	0.9055	0.9416
12	6440009	G	0.383	0.3758	А	0.9138	1.031
1	85746993	А	0.08511	0.09073	G	1	0.9323
1	20087472	G	0.2766	0.2766	А	1	0.9999
	8						
8	79575804	Α	0.2447	0.2504	G	1	0.9697

Supplemental Appendix 1. Participants of Adjudication Meetings

Name	Institution
Tariq Ahmad	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
Alasdair Coles	Department of Clinical Neurosciences, University of Cambridge, UK
James R. Goodhand	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
Timothy Harrower	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
Graham A. Heap	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
Neel Heerasing	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
Peter Hendy	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
Jeremy Hobart	Department of Neurology, University Hospitals Plymouth, Plymouth, UK
Nicholas Kennedy	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
Simeng Lin	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
Roswell Martin	Department of Neurology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK
Gareth J. Walker	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
Alexander Spiers	Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK

Supplemental Appendix 2: PRED4 study group members

Country	Hospital or Trust name	City	Name	Job Title	Highest academic qualification
Australia	Mater Research Institute – University of Queensland	Brisbane	Professor Timothy H Florin	Consultant Gastroenterologist	MBBS
Australia	Canberra Hospital	Canberra	Dr Kavitha	Consultant	MBBS
Australia		Caliberta	Subramaniam	Gastroenterologist	IVIDD5
Canada	University of Alberta	Edmonton	Dr Richard	Professor of Medicine	MD
canada			N Fedorak	in Gastroenterology	
Canada	Mount Sinai Hospital	Toronto	Dr Mark Silverberg	Consultant	PhD
				Gastroenterologist	
Denmark	Hospital of Southern	Jutland	Professor Vibeke	Clinical Professor	MD
	Jutland		Andersen		
United	Aberdeen Royal Infirmary,	Aberdeen	Dr Malcolm Smith	Consultant	MBChB
Kingdom	NHS Grampian	•		Gastroenterologist	
United	Stoke Mandeville Hospital	Aylesbury	Dr David Gorard	Consultant	MD
Kingdom				Gastroenterologist	
United	Northern Devon Healthcare	Barnstaple	Dr Alex Moran	Consultant	MD
Kingdom	Trust			Gastroenterologist	
United	Heart of England NHS	Birmingham	Dr Naveen Sharma	Consultant	PhD
Kingdom	Foundation Trust			Gastroenterologist	
United	Queen Elizabeth Hospital	Birmingham	Dr Tariq Iqbal	Consultant	MD
Kingdom				Gastroenterologist	
United	University of Cambridge	Cambridge	Professor Alasdair	Professor of	PhD
Kingdom			Coles	Neuroimmunology	
United	Addenbrooke's Hospital,	Cambridge	Dr Miles Parkes	Consultant	DM
Kingdom	Cambridge University		9	Gastroenterologist	
	Hospitals NHS Foundation				
	Trust				
United		Edinburgh	Dr Charlie W Lees	Consultant	PhD
Kingdom	NHS Lothian			Gastroenterologist	
United	Royal Devon and Exeter NHS	Exeter	Dr Tariq Ahmad	Consultant	DPhil
Kingdom	Foundation Trust			Gastroenterologist	
United	Royal Devon and Exeter	Exeter	Dr Neil Chanchlani	IBD Research Fellow	MBChB
Kingdom	Hospital NHS Foundation				
	Trust				
United	Royal Devon and Exeter NHS	Exeter	Dr James	Consultant	MBBS
Kingdom	Foundation Trust		R Goodhand	Gastroenterologist	
United	Royal Devon and Exeter NHS	Exeter	Dr Benjamin	IBD Research Fellow	MBBS
Kingdom	Foundation Trust		Hamilton		
United	Royal Devon and Exeter NHS	Exeter	Dr Timothy	Consultant Neurologist	PhD
Kingdom	Foundation Trust		Harrower		
United	Royal Devon and Exeter	Exeter	Dr Graham A Heap	IBD Research Fellow	PhD
Kingdom	NHS Foundation Trust				
United	Royal Devon and Exeter NHS	Exeter	Dr Neel	IBD Research Fellow	MBBS
Kingdom	Foundation Trust		M Heerasing		
United	Royal Devon and Exeter NHS	Exeter	Dr Peter Hendy	IBD Research Fellow	MBBS
Kingdom	Foundation Trust				
United	Royal Devon and Exeter NHS	Exeter	Dr Nicholas A	Consultant	MBBS
Kingdom	Foundation Trust		Kennedy	Gastroenterologist	

United Kingdom	Royal Devon and Exeter NHS Foundation Trust	Exeter	Dr Simeng Lin	IBD Research Fellow	MBCh
United	Royal Devon and Exeter NHS Foundation Trust	Exeter	Dr Alexander Spiers	Consultant Radiologist	вмвс
Kingdom United Kingdom	Royal Devon and Exeter NHS Foundation Trust	Exeter	Dr Gareth J Walker	IBD Research Fellow	PhD
United Kingdom	University of Exeter	Exeter	Ms Claire M Bewshea	Group Manager	MSC
United Kingdom	University of Exeter	Exeter	Mrs Hanlie Olivier	Research Administrator	MATR
United Kingdom	University of Exeter Medical School	Exeter	Dr Harry D Green	Postdoctoral Research Fellow	PhD
United Kingdom	University of Exeter Medical School	Exeter	Dr Michael Weedon	Associate Professor in Genetics	PhD
United Kingdom	Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde	Glasgow	Dr Daniel R Gaya	Consultant Gastroenterologist	MD
United Kingdom		Glasgow	Professor Richard K Russell	Consultant Paediatric Gastroenterologist	PhD
United Kingdom	Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Foundation Trust	Gloucester	Dr Paul Dunckley	Consultant Gastroenterologist	DPhil
United Kingdom	Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Foundation Trust	Gloucester	Dr Roswell J Martin	Consultant Neurologist	MD
United Kingdom		Harrogate	Dr Joanne Ridpath	Consultant Gastroenterologist	BM
United Kingdom	Hull and East Yorkshire Hospitals NHS Trust	Hull	Dr Shaji Sebastian	Consultant Gastroenterologist	MD
United Kingdom	Airedale NHS Foundation Trust	Keighley	Dr Richard Shenderay	Consultant Gastroenterologist	MBBS
United Kingdom	East Kent Hospitals University NHS Foundation Trust	Kent	Dr Michael P Delaney	Consultant Nephrologist	MD
United Kingdom	Royal Liverpool and Broadgreen U niversity Hospital NHS Trust	Liverpool	Dr Sreedhar 🧼 Subramanian	Consultant Gastroenterologist	MD
United Kingdom	Guy's and St Thomas' Hospital NHS Foundation Trust	London	Dr Peter M Irving	Consultant Gastroenterologist	MD
United Kingdom	King's College Hospital	London	Dr Guy Chung-Faye	Consultant Gastroenterologist	PhD
United Kingdom	Royal Free Hospital, Royal Free London NHS Foundation Trust	London	Dr Charles Murray	Consultant Gastroenterologist	PhD
United Kingdom	University College London Hospitals	London	Dr Stuart Bloom	Consultant Gastroenterologist	DM
United Kingdom	Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals NHS Foundation Trust	Newcastle upon Tyne	Dr John C Mansfield	Consultant Gastroenterologist	MD

United Kingdom	Oxford University Hospitals	Oxford	Professor Alison Simmons	Consultant Gastroenterologist	PhD
United Kingdom	Derriford Hospital, University Hospitals Plymouth NHS Trust	Plymouth	Professor Jeremy Hobart	Consultant Neurologist	PhD
United Kingdom	Royal Berkshire Hospital	Reading	Dr Jonathan D Simmons	Consultant Gastroenterologist	DM
United Kingdom	Salford Royal NHS Foundation Trust	Salford	Professor Simon Lal	Consultant Gastroenterologist	PhD
United Kingdom	Royal Hallamshire Hospital	Sheffield	Professor Alan Lobo	Consultant Gastroenterologist	MD
United Kingdom	Southampton General Hospital	Southampton	Dr Richard Felwick	Consultant Gastroenterologist	PhD
United Kingdom	Southampton General Hospital	Southampton	Dr JR Fraser Cummings	Consultant Gastroenterologist	DPhi
United Kingdom	Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust	Taunton	Dr Emma R Greig	Consultant Gastroenterologist	PhD
United Kingdom	Torbay and South Devon NHS Foundation Trust	Torquay	Dr Mark Feeney	Consultant Gastroenterologist	MD
United Kingdom	Royal Cornwall Hospital Trust	Truro	Dr John Beckly	Consultant Gastroenterologist	MD
United Kingdom	The Mid Yorkshire Hospitals NHS Trust	Wakefield	Dr Deven Vani	Consultant Gastroenterologist	MD
United Kingdom	New Cross Hospital, The Royal Wolverhampton Hospitals NHS Trust	Wolverhampton	Dr Matthew J Brookes	Consultant Gastroenterologist	PhD
United Kingdom	Worthing Hospital, Western Sussex Hospitals	Worthing	Dr Zinu Philipose	Consultant Gastroenterologist	MBB
United Kingdom	Yeovil District Hospital	Yeovil	Dr Steve Core	Consultant Gastroenterologist	MD

Supplemental Appendix 3. Case Report Form

International IBD Genetics Consortium

PRED4

Anti-TNF α Induced Demyelination

Case Report Form

Please stick study label here

On completion, please return to: IBD Pharmacogenetics Research Office The Research, Innovation, Learning and Development Centre (RILD) Barrack Road Exeter EX2 5DW

Please complete all boxes where indicated and in black ball point pen.

If you make a mistake please put a line through the box, initial and date and write answer to the side.

Complete dates in format dd/mm/yyyy

The patient identification number is the bar code on the front of the CRF. Please transcribe this on to the top of the page in each relevant section.

For study inclusion participants must meet all the major criteria and any number of the additional minor criteria.

*Other potential causes of neurological symptoms

Acute disseminated encephalomyelitis (ADEM), Behcet's disease, polyarteritis nodosa, Sjögren's disease, anti-phospholipid syndrome, systemic lupus erythematosus (SLE), sarcoid, Infections (such as HIV, Lyme, neurosyphilis, Listeria, Progressive multifocal leukoencephalopathy [PML]), Vitamin B12 deficiency

This study covers both central nervous system (CNS) and peripheral nervous system (PNS) demyelination.

Page 2 of 12

 International IBD Genetics Consortium

Anti-TNFa Induced Demyelination in IBD CRF v3.0 (June 2014)

Sec	tion 1 - Inclusion Criteria Study code
1.1	Major criteria (all must be met)
\Box	History of exposure to anti-TNF $lpha$ antibody at any time in the past
	No history of demyelinating neurological symptoms prior to exposure to Anti-TNFo antibody
\Box	Neurological symptoms lasting at least 24 hours
	MRI brain and/or spinal cord shows changes consistent with CNS demyelination; or electrophysiological tests (nerve conduction or evoked potentials) are consistent w PNS or CNS demyelination.
	CNS or PNS inflammatory demyelination confirmed by Neurologist
	Neurological opinion implicates anti-TNF α medication as possible cause of demyelination, and if the patient is still receiving the drug, it is withdrawn
1.2	Other potential causes for neurological symptoms (see page 2)*
\Box	No - Category A
	Yes - Category B
	If yes, please specify
1.3	Minor criteria:
\Box	Resolution (partial or complete) of symptoms on drug withdrawal (with or withour specific treatment)
\Box	Recurrence of symptoms on re-challenge with anti-TNF $lpha$ antibody
1.4	Number of minor criteria
	Participant's eligibility Investigator sign-off
	e participant eligible to take part in the clinical trial? Yes No
	p, please give reason(s) for screen failure:
1.	
2.	
3.	
Inve	stigator's signature Date dd / mm / yyyy
Inve	stigator's name (print)

Section 2 - Patient Details	Study code
2.1 Patient details	
Date of Birth dd / mm / yyyy	Sex: M 💭 F 🗌
Weight at time of initial anti-TNF $lpha$ dose (c	or nearest weight) kg
Height cm	
2.2 Ethnicity - Please tick as approp	riate
White	Black or Black British
British	Caribbean
lrish	African
Any other White background	Any other Black background
Mixed	Chinese or Other Ethnic Group
White and Black Caribbean	Chinese
White and Black African	Any other ethnic group (<i>please specify</i>
White and Asian	
Any other Mixed background	Not stated
Asian or Asian background	
Indian	
Pakistani	
Bangladeshi	
Any other Asian background	
2.3 Participant informed consent	
Date participant signed written consent fo	orm dd / mm / yyyy
Date of blood sample taken	dd / mm / yyyy

Page 4 of 12

International IBD Genetics Consortium Anti-TNFα Induced Demyelination in IBD CRF v3.0 (June 2014)

	AI Section 3 - Medical		ed Demyelination Study code
3.1.1 Consultant Gastroenterologist/ Rheumatologist/Dermatologist 3.1.2 Consultant Neurologist	3.1 Hospital Details	;	
Hospital address Hospital address Hospital address Image: Consultant telephone Consultant telephone Consultant telephone Consultant email Consultant email Consultant email Consultant email 3.2 Medical History Salant email S.1 Indication for Anti-TNFα medication: Inflammatory bowel disease – Crohn's Disease/Ulcerative Colitis Rheumatoid Arthritis Ankylosing Spondylitis Seronegative spondyloarthropathies Psoriasis Other, please specify: Salant email 3.3 Comorbidities Yes No Date of diagnosis dd / mm / yyyy 3.3.1 Hypertension Yes No Date of diagnosis dd / mm / yyyy Type I Using insulin: Yes No	3.1.1 Consultant Gastro	enterologist/	3.1.2 Consultant Neurologist
Consultant telephone Consultant telephone Consultant email Consultant email Consultant email Consultant email 3.2 Medical History 3.2.1 Indication for Anti-TNFα medication: □ Inflammatory bowel disease – Crohn's Disease/Ulcerative Colitis □ Rheumatoid Arthritis □ Ankylosing Spondylitis □ Seronegative spondyloarthropathies □ Psoriasis □ Other, please specify: 3.3.1 Hypertension Yes □ Type I □ Using insulin: □ Yes	Hospital		Hospital
Consultant telephone Consultant telephone Consultant email Consultant email Consultant email Consultant email 3.2 Medical History 3.2.1 Indication for Anti-TNFα medication: □ Inflammatory bowel disease – Crohn's Disease/Ulcerative Colitis □ Rheumatoid Arthritis □ Ankylosing Spondylitis □ Seronegative spondyloarthropathies □ Psoriasis □ Other, please specify: 3.3.1 Hypertension Yes □ Type I □ Using insulin: □ Yes			
Consultant email Consultant email Consultant email Consultant email 3.2 Medical History 3.2 Medical History 3.2.1 Indication for Anti-TNFα medication: Inflammatory bowel disease – Crohn's Disease/Ulcerative Colitis Rheumatoid Arthritis Ankylosing Spondylitis Seronegative spondyloarthropathies Psoriasis Other, please specify:	Hospital address		Hospital address
Consultant email Consultant email Consultant email Consultant email 3.2 Medical History 3.2 Medical History 3.2.1 Indication for Anti-TNFα medication: Inflammatory bowel disease – Crohn's Disease/Ulcerative Colitis Rheumatoid Arthritis Ankylosing Spondylitis Seronegative spondyloarthropathies Psoriasis Other, please specify:	Consultant telephone		Consultant telephone
3.2 Medical History 3.2.1 Indication for Anti-TNFα medication: □ Inflammatory bowel disease – Crohn's Disease/Ulcerative Colitis □ Rheumatoid Arthritis □ Ankylosing Spondylitis □ Seronegative spondyloarthropathies □ Psoriasis □ Other, please specify: 3.3 Comorbidities Yes No 3.3.1 Hypertension Yes Yes No Date of diagnosis dd / mm / yyyy □ Type I Using insulin:			
3.2.1 Indication for Anti-TNFα medication: Inflammatory bowel disease – Crohn's Disease/Ulcerative Colitis Rheumatoid Arthritis Ankylosing Spondylitis Seronegative spondyloarthropathies Psoriasis Other, please specify: 3.3 Comorbidities Yes No Date of diagnosis dd / mm / yyyy S.2.2 Diabetes Yes No Date of diagnosis dd / mm / yyyy	Consultant email		Consultant email
3.2.1 Indication for Anti-TNFα medication: Inflammatory bowel disease – Crohn's Disease/Ulcerative Colitis Rheumatoid Arthritis Ankylosing Spondylitis Seronegative spondyloarthropathies Psoriasis Other, please specify: 3.3 Comorbidities Yes No Date of diagnosis dd / mm / yyyy S.2.Diabetes Yes No Date of diagnosis dd / mm / yyyy			
3.3.1 Hypertension Yes No Date of diagnosis dd / mm / yyyy 3.3.2 Diabetes Yes No Date of diagnosis dd / mm / yyyy Type I Using insulin: Yes No	3.2.1 Indication for Ant Inflammatory Rheumatoid A Ankylosing Sp Seronegative Psoriasis Other, please	i-TNFα medication: bowel disease – Croh Arthritis bondylitis spondyloarthropathie	
3.3.2 Diabetes Yes No Date of diagnosis dd / mm / yyyy Type I Using insulin: Yes No	3.3 Comorbidities	Yes No	
Type I Using insulin: Yes No	3.3.1 Hypertension	Yes No	Date of diagnosis dd / mm / yyyy
	3.3.2 Diabetes	Yes No	Date of diagnosis dd / mm / yyyy
	Туре І		Using insulin: Yes No
Date commenced insulin dd / mm / yyy	Type II		Date commenced insulin dd / mm / yyyy

International IBD Genetics Consortium

Anti-TNF α Induced Demyelination in IBD CRF v3.0 (June 2014)

 Page 5 of 12

	Stud	ly code
3.3.3 Severe peripheral vascular disease	Yes	No
Date of diagnosis dd / mm / yyyy		
3.3.4Myocardial infarction	Yes	No No
Date of diagnosis dd / mm / yyyy		
3.3.5TIA/CVA	Yes	No
Date of diagnosis dd / mm / yyyy		
3.4 Other significant medical history	Yes	No
f yes, please give details here		
2.5. Smoking History		
3.5 Smoking History		
3.5.1 Never Smoked Ex Smoker		Current Smoker
3.5.1 Never Smoked Ex Smoker 3.5.2 Start Date dd / mm / yyyy		Current Smoker
3.5.1 Never Smoked Ex Smoker		Current Smoker
3.5.1 Never Smoked Ex Smoker 3.5.2 Start Date dd / mm / yyyy		Current Smoker
3.5.1 Never Smoked Ex Smoker 3.5.2 Start Date dd / mm / yyyy 3.5.3 End Date dd / mm / yyyy		Current Smoker

Anti-TNF α Induced Demyelination in IBD CRF v3.0 (June 2014)

Anti-TNF α Induced Demyelination

Section 4 - Anti-TNF α History

Study code

4.1 Anti-TNFα Medication

	Date Anti-TNFα Medication commenced	Date Anti-TNFα Medication ceased	Dose of Anti-TNFα Medication	Number of doses
Infliximab	dd / mm / yyyy	dd /mm/ yyyy		
Adalimumab	dd / mm / yyyy	dd /mm/ yyyy		
Certolizumab pegol	dd / mm / yyyy	dd /mm/ yyyy		
Etanercept	dd / mm / yyyy	dd /mm/ yyyy		
Other, please specify	dd / mm / yyyy	dd /mm/ yyyy		

4.2 Date of onset of neurological symptoms

dd / mm / yyyy

4.3 Please describe the patient's symptoms

4.4 Please describe the neurological examination findings

International IBD Genetics Consortium Anti-TNFα Induced Demyelination in IBD CRF v3.0 (June 2014)

Page 7 of 12

Section 4 - Anti-TNF α	History	Study code
4.5 Had the patient ev onset of this episo		and/or spinal cord BEFOR
Yes No	D Unknown	
If yes what was the d	ate of this scan	dd / mm / yyyy
Was a contrast agent	used? Yes	No Unkno
If yes, please specify		
Please copy report te	xt below or attach photo	copy of report after anonymis
4.6 Did the natient ha	ve an MRI Brain and/	or spinal cord AFTER the
4.6 Did the patient ha neurological symp		or spinal cord AFTER the
	otoms?	or spinal cord AFTER the
neurological symp	otoms?	or spinal cord AFTER the
neurological symp	otoms?	dd / mm / yyyy
neurological symp Yes No If yes what was the d	otoms?	dd / mm / yyyy
neurological symp Yes No If yes what was the d Was a contrast agent If yes, please specify	otoms? D Unknown ate of this scan used? Yes	dd / mm / yyyy
neurological symp Yes No If yes what was the d Was a contrast agent If yes, please specify	otoms? D Unknown ate of this scan used? Yes	dd / mm / yyyy
neurological symp Yes No If yes what was the d Was a contrast agent If yes, please specify	otoms? D Unknown ate of this scan used? Yes	dd / mm / yyyy
neurological symp Yes No If yes what was the d Was a contrast agent If yes, please specify	otoms? D Unknown ate of this scan used? Yes	dd / mm / yyyy
neurological symp Yes No If yes what was the d Was a contrast agent If yes, please specify	otoms? D Unknown ate of this scan used? Yes	dd / mm / yyyy
neurological symp Yes No If yes what was the d Was a contrast agent If yes, please specify	otoms? D Unknown ate of this scan used? Yes	dd / mm / yyyy
neurological symp Yes No If yes what was the d Was a contrast agent If yes, please specify	otoms? D Unknown ate of this scan used? Yes	dd / mm / yyyy
neurological symp Yes No If yes what was the d Was a contrast agent If yes, please specify	otoms? D Unknown ate of this scan used? Yes	dd / mm / yyyy
neurological symp Yes No If yes what was the d Was a contrast agent If yes, please specify	otoms? D Unknown ate of this scan used? Yes	

C	ction 4 - Anti-TNFa History Study code	
7	7 Did the patient have a lumbar puncture/CSF examination?	
	If yes, please give findings or attach photocopy of report after anonymi	sation
3	3 Did the patient have evoked potentials (EP) carried out - Vis Somatosensory (SSEP) or Brainstem Auditory (BAEP)?	ual (VEP),
	Yes No Unknown	
	Please copy report text below or attach photocopy of report after anon	vmisation
•	 Did the patient have nerve conducting studies? Yes No Unknown Please copy report text below or attach photocopy of report after anon 	ymisation
10	I0 Did the patient have any other investigations?	
	Yes No Unknown	
	If yes, please give details	

Section 4 - /	Anti-TNFa History Study code
4.11 Did the	patient require hospital admission?
Yes	No Unknown
If yes:	Date of admission dd / mm / yyyy
	Date of discharge dd / mm / yyyy
4.12 Did the	patient require any specific treatment?
Yes	No Unknown
If yes, wh	nat treatment was given?
🗌 Intra	avenous Immunoglobulin (IVIG)
Ster	
\subseteq	ma exchange
U Othe	er, please specify
4.13 Disease	course (please tick one of the following)
Episo	ode of demyelination with complete resolution of symptoms
How	long did it take for symptoms to resolve (days)?
)(ode of demyelination with partial or no resolution of symptoms
	pse-remitting episodes, characterised by further acute symptoms of yelination
	ressive symptoms
<u> </u>	e patient rechallenged with the same or another anti-TNF $lpha$
agent?	patient rechancinged with the same of another and thing
Yes	No Unknown
If yes:	Which anti-TNFα was used?
	Date started dd / mm / yyyy Dose and frequency
	Did symptoms recur? Yes No Unkno
	If Yes Date of recurrence dd / mm / yyyy
	Details
	Date of Drug withdrawal dd / mm / yyyy
4455	Date of Drug withdrawal dd / mm / yyyy
	nistory of multiple sclerosis or peripheral nerve disorder?
Yes	nistory of multiple sclerosis or peripheral nerve disorder?
Yes	nistory of multiple sclerosis or peripheral nerve disorder?

Anti-TNF α	Induced	Demve	lination
	maacca	Deniye	mation

Section 4 - Anti-TNF $lpha$ Histo	ry
-----------------------------------	----

Study code

4.16 Family history of anti-TNFα induced demyelination?

Y	es	L) No
lf yes,	please	give	details

Unknown

s

Section 5 - Other Drug History

(in the last 3 months prior to development of neurological symptoms)

Drug name	Dose and Route	Start date	Stop date
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy

International IBD Genetics Consortium

Anti-TNF α Induced Demyelination in IBD CRF v3.0 (June 2014)

Page 11 of 12

reflec	ts the study	information obt	ained for this pa	rticipant. All er	vledge, it accurate tries were made e Delegation Log.
Princi	pal Investig	ator's signature			
Date	dd	l / mm / yyyy			
Princi	pal Investig	ator's name (prin	nt)		